Macromolecular and nanotechnological modification of camptothecin and its analogs to improve the efficacy

Current Drug Discovery Technologies

Volumn 2, Issue 3, 2005, Pages 169-183

  Onishi, Hiraku ^a   Machida, Yoshiharu ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Analog; Camptothecin (CPT); Enhanced permeability and retention (EPR) effect; Macromolecular chemical modification; Nanotechnological formulation

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CARBOXYMETHYLDEXTRAN; DOXORUBICIN; ETHYLENE GLYCOL; IRINOTECAN; LACTONE; LIPOSOME; MACROGOL; MACROGOL DERIVATIVE; METHOXYPOLYETHYLENE GLYCOL; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; POLYGLUTAMIC ACID; SOLID LIPID NANOPARTICLE; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; COVALENT BOND; DISPERSION; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; ENTEROPATHY; HUMAN; LIVER METASTASIS; MACROMOLECULE; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DEXTRANS; HT29 CELLS; HUMANS; LIPOSOMES; NANOSTRUCTURES; NEOPLASM TRANSPLANTATION; POLYMERS; POLYMETHACRYLIC ACIDS; PRODRUGS; TOPOTECAN; TREATMENT OUTCOME;

EID: 24144457231     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570163054866891     Document Type: Article

References (72)

1. Wall M.E., Wni M.C., Cook C.E., Palmer K.H., McPhail A.T., Sim G.A.: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J. Am. Chem. Soc. 88, 3888, (1996).
2. Huang S.-Y.: Seven hundred herbal prescriptions for cancer medicine treatment, Bada Educational and Cultural Publishers: Taipei (1986).
3. Gottlieb J.A., Guarino A.M., Call J.B., Oliverio V.T., Block J.B.: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep. 54(6), 461, (1970).
4. Moertel G.G., Schutt A.J., Reitemeier R.J., Hahn R.G.: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56(1), 95, (1972).
5. Gottlieb J.A., Luce J.K.: Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep. 56(1), 103, (1972).
6. Muggia F.M., Creaven P.J., Hansen H.H., Cohen M.H., Sealwry O.S.: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep. 56(4), 515, (1972).
7. Hsiang Y.H., Liu L.F., Wall M.E., Wani M.C., Nicholas A.W., Manikumar G., Kirschenbaum S., Silber R., et al.: DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analog. Cancer Res. 49(16), 4385, (1989).
8. Giovanella B.C., Hinz H.R., Kozielski A.J., Stehlin J.S. Jr., Silber R., Potmesil M.: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. 51(11), 3052, (1991).
9. Potmesil M.: Camptothecins: from bench research to hospital wards. Cancer Res. 54(6), 1431, (1994).
10. Pantazis P., Kozielski A.J., Mendoza J.T., Early J.A., Hinz H.R., Giovanella B.C.: Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int. J. Cancer 53(5), 863, (1993).
11. Kunimoto T., Nitta K., Tanaka T., Uehara N., Baba H., Takeuchi M., Yokokura T., Sawada S., et al: Antitumor activity of 7-ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47(22), 5944, (1987).
12. Houghton P.J., Cheshire P.J., Myers L., Stewart C.F., Synold T.W., Houghton J.A.: Evaluation of 9-dimethylaminomethyl - 10 - hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol. 31(3), 229, (1992).
13. Kaneda N., Nagata H., Furuta T., Yokokura T.: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50(6), 1715, (1990).
14. Kawato Y., Aonuma M., Hirota Y., Kuga H., Sato K.: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51(16), 4187, (1991).
15. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F.: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 260(27), 14873, (1985).
16. Hsiang Y.H., Liu L.F.: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48(7), 1722, (1988).
17. Jaxel C., Kohn K.W., Wani M.C, Wall M.E., Pommier Y.: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 49(6), 1465, (1989).
18. Hashida M., Takakura Y.: Pharmacokinetics in design of polymeric drug delivery systems. J. Control. Release 31(2), 163, (1994).
19. Takakura Y., Hashida M.: Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res. 13(6), 820, (1996).
20. Yamaoka T., Tabata Y., Ikada, Y.: Fate of water-soluble polymers administered via different routes. J. Pharm. Sci. 84(3), 349(1995).
21. Tabata Y., Murakami Y., Ikada Y.: Tumor accumulation of poly (vinyl alcohol) of different sizes after intravenous injection. J. Control. Release 50(1-3), 123, (1998).
22. Klibanov A.L., Maruyama K., Beckerleg A.M., Torchilin V.P., Huang L.: Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta 1062(2), 142, (1991).
23. Senior J., Delgado C., Fisher D., Tilcock C., Gregoriadis G.: Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta 1062(1), 77, (1991).
24. Yokoyama M., Okano T., Sakurai Y., Ekimoto H., Shibazaki C., Kataoka K.: Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 51(12), 3229, (1991).
25. Kwon G.S., Yokoyama M., Okano T., Sakurai Y., Kataoka K.: Biodistribution of micelle-forming polymer-drug conjugates. Pharm Res. 10(7), 970, (1993).
26. Matsumura Y., Maeda H.: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (12 Pt 1), 6387, (1986).
27. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K.: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65(1-2), 271, (200O).
28. Maeda H.: SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 46(1-3), 169, (2001).
29. Unezaki S., Maruyama K., Ishida O., Suginaka A., Hosoda J., Iwatsuru M.: Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethylene glycol). Int. J. Pharm. 126(1-2), 41, (1995).
30. Nakanishi T., Fukushima S., Okamoto K., Suzuki M., Matsumura Y., Yokoyama M., Okano T., Sakurai Y., et al.: Development of the polymer micelle carrier system for doxorubicin. J. Control. Release 74(1-3), 295, (2001).
31. Trouet A., Masquelier M., Baurain R., Deprez-De Campeneere D.: A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. U.S.A. 79(2), 626, (1982).
32. Burger A.M., Hartung G., Stehle G., Sinn H., Fiebig H.H.: Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int. J. Cancer. 92(5), 718, (2001).
33. Hashida M., Takakura Y., Matsumoto S., Sasaki H., Kato A., Kojima T., Muranishi S., Sezaki H.: Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity. Chem. Pharm. Bull. 31(6), 2055, (1983).
34. Duncan R., Seymour L.W., O'Hare K.B., Flanagan P.A., Wedge, S., Hume I.C., Ulbrich K., Strohalm J., et al.: Preclinical evaluation of polymer-bound doxorubicin. J. Control. Release 19(1-3), 331, (1992).
35. Takakura Y., Takagi A., Hashida M., Sezaki H.: Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 4(4), 293, (1987).
36. Takakura Y., Fujita T., Hashida M., Sezaki H.: Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res., 1990, 7(4), 339, (1990).
37. Inaba M.: Abstract of Research Works for the General Research A of Subject Number 05302061 with a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan: pp. 57-61, (1996).
38. Greenwald R.B., Pendri A., Conover C., Gilbert C., Yang R., Xia J.: Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. J. Med. Chem. 39(10), 1938, (1996).
39. Conover C.D., Greenwald R.B., Pendri A., Gilbert C.W., Shum K.L.: Camptothecin delivery systems: enhanced efficacy and tumor accumulation of Camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother. Pharmacol. 42(5), 407, (1998).
40. Greenwald R.B., Choe Y.H., McGuire J., Conover C.D.: Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55(2), 217, (2003).
41. Caiolfa V.R., Zamai M., Fiorino A., Frigerio E., Pellizzoni C., d'Argy R., Ghiglieri A., Castelli M.G., et al.: Polymer-bound Camptothecin: initial biodistribution and antitumour activity studies. J. Control. Release 65(1-2), 105, (2000).
42. Sakuma S., Lu Z.R., Kopeckova P., Kopecek J.: Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin. J. Control. Release 75(3), 365, (2001).
43. Singer J.W., De Vries P., Bhatt R., Tulinsky J., Klein P., Li C., Milas L., Lewis R.A., et al.: Conjugation of camptothecins to poly-(L-glutamic acid). Ann. N. Y. Acad. Sci. 922, 136, (2000).
44. Singer J.W., Bhatt R., Tulinsky J., Buhler K.R., Heasley E., Klein P., de Vries P.: Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J. Control. Release 74(1-3), 243, (2001).
45. Okuno S., Harada M., Yano T., Yano S., Kiuchi S., Tsuda N., Sakamura Y., Imai J., et al.: Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res. 60(11), 2988, (2000).
46. Harada M., Sakakibara H., Yano T., Suzuki T., Okuno S.: Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate. J. Control. Release 69(3), 399, (2000).
47. Conover C.D., Pendri A., Lee C., Gilbert C.W., Shum K.L., Greenwald R.B.: Camptothecin delivery systems: the antitumor activity of a camptothecin-20-0- polyethylene glycol ester transport form. Anticancer Res. 17(5A), 3361, (1997).
48. Greenwald R.B., Pendri A., Conover C.D., Lee C., Choe Y.H., Gilbert C., Martinez A., Xia J., et al: Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. Bioorg. Med. Chem. 6(5), 551, (1998).
49. Murakami Y., Tabata Y., Ikada Y.: Tumor accumulation of poly(ethylene glycol) with different molecular weights after intravenous administration. Drug Delivery 4, 23, (1997).
50. Potmesil M., Vardeman D., Kozielski A.J., Mendoza J., Stehlin J.S., Giovanella B.C.: Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res. 55(23), 5637, (1995).
51. Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicolas A.W., Liu L.F., Silber R., Pomesil M.: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246(4933), 1046, (1989).
52. Brazeau G. A., Fung H.L.: Physicochemical properties of binary organic cosolvent-water mixtures and their relationships to muscle damage following intramuscular injection.: J. Parenter. Sci. Technol. 43(4), 144, (1989).
53. Gupta P.K., Patel J.P., Hahn K.R.: Evaluation of pain and irritation following local administration of par enteral formulations using the rat paw lick model. J. Pharm. Sci. Technol. 48(3), 159, (1994).
54. Benita S., Levy M.Y.: Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterization. J. Pharm. Sci. 82(11), 1069, (1993).
55. Woodle M.C., Lasic D.D.: Sterically stabilized liposomes. Biochim. Biophys. Acta 1113(2), 171, (1992).
56. Lasic D.D.: Doxorubicin in sterically stabilized liposomes. Nature 380(6574), 561, (1996).
57. Azori M.: Polymericprodrugs. Crit. Rev. Ther. Drug Carrier Syst. 4(1), 39, (1987).
58. Merisko-Liversidge E., Sarpotdar P., Bruno J., Hajj S., Wei L., Felder N., Rake J., Shaw J.M., et al: Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res. 13(2), 272, (1996).
59. Peters K., Leitzke S., Diederichs I.E., Borner K., Hahn H., Muller R.H., Ehlers S. J.: Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. Antimicrob. Chemother. 45(1), 77, (2000).
60. Yang S.C., Lu L.F., Cai Y., Zhu J.B., Liang B.W., Yang C.Z.: Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release 59(3), 299, (1999).
61. Dunn S.E., Coombes A.G.A., Garnett M.C., Davis S.S., Davies M.C., Ilium L.: In vitro cell interaction and in vivo biodistribution of poly(lactide-coglycolide) nanospheres surface modified by poloxamer and poloxamine copolymers. J. Control. Release 44(1), 65, (1997).
62. Kurihara A., Shibayama Y., Mizota A., Yasuno A., Ikeda M., Sasagawa K., Kobayashi T., Hisaoka M.: Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice. Pharm. Res. 13(2), 305, (1996).
63. Daoud S.S., Fetouh M.I., Giovanella B.C.: Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts. Anticancer Drugs 6(1), 83, (1995).
64. Sadzuka Y., Hirotsu S., Hirota S.: Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett. 127(1-2), 99, (1998).
65. Sadzuka Y.: Effective prodrug liposome and conversion to active metabolite. Curr. Drug Metab. 1(1), 31, (200O).
66. Machida Y., Onishi H., Morikawa A., Machida Y.: Antitumor characteristics of irinotecan-containing microspheres of poly-d,l-lactic acid or poly(d,l-lactic acid-co-glycolic acid) copolymers. S.T.P. Pharma Sci. 8(3), 175, (1998).
67. Machida Y., Onishi H., Kurita A., Hata H., Morikawa A., Machida Y.: Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats. J. Control. Release 66(2-3), 159, (2000).
68. Machida Y., Onishi H., Kato Y., Machida Y.: Efficacy of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) against M5076 tumor in the early liver metastatic stage. S.T.P. Pharma Sci. 13(4), 225, (2003).
69. Ishida O., Maruyama K., Sasaki K., Iwatsuru M.: Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int. J. Pharm. 190(1), 49, (1999).
70. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R.: Biodegradable long-circulating polymeric nanospheres. Science 263(5153), 1600, (1994).
71. Bazile D., Prud'homme C., Bassoullet M.T., Marlard M., Spenlehauer G., Veillard, M.: Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84(4), 493, (1995).
72. Miura H., Onishi H., Sasatsu M., Machida Y.: Antitumor characteristics of methoxypolyethylene glycol-poly (DL-lactic acid) nanoparticles containing camptothecin. J. Control. Release 97(1), 101, (2004).